Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Genmab A/S's quarterly P/E stands at 11.8x, up 277.4% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 663.2% YoY to 9.1x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 15.36 | 11.80 | 1.51 | 15.79 | 0.87 | 3.13 | 2.90 | 3.70 | 8.21 | 2.73 | 4.61 | 29.50 | 12.04 |
| — | +277.4% | -47.8% | +326.6% | -89.4% | +14.5% | -37.2% | -87.5% | -31.8% | +33.2% | +63.0% | +131.6% | +31.5% | |
| P/S Ratio | 5.34 | 4.66 | 0.55 | 4.38 | 0.52 | 0.71 | 5.23 | 8.14 | 1.12 | 1.23 | 1.50 | 2.19 | 1.36 |
| — | +552.4% | -89.6% | -46.2% | -53.6% | -42.1% | +248.7% | +271.3% | -17.9% | -4.9% | -11.5% | -22.1% | -45.4% | |
| P/B Ratio | 3.28 | 3.31 | 0.38 | 0.37 | 0.36 | 0.50 | 0.53 | 0.60 | 0.66 | 0.75 | 0.87 | 0.91 | 1.03 |
| — | +568.0% | -27.6% | -38.3% | -44.9% | -33.6% | -39.5% | -33.9% | -35.4% | -6.0% | -0.6% | -13.0% | -12.9% | |
| P/FCF | 15.15 | 8.91 | 9.72 | 1.79 | 11.18 | 1.99 | 18.96 | 22.84 | 3.26 | 3.00 | 18.46 | 1.98 | 24.31 |
| — | +347.4% | -48.8% | -92.2% | +242.6% | -33.5% | +2.7% | +1050.5% | -86.6% | +6.7% | +206.8% | -82.4% | -35.7% | |
| EV / EBITDA | 14.90 | 9.13 | 0.58 | 6.43 | 0.51 | 1.20 | 12.99 | 11.59 | 0.99 | 1.38 | 2.46 | 7.11 | 1.78 |
| — | +663.2% | -95.5% | -44.5% | -48.8% | -13.2% | +428.9% | +62.9% | -44.4% | -3.9% | +5.0% | +7.7% | -64.9% | |
| EV / EBIT | 15.82 | 8.98 | 0.51 | 5.26 | 0.50 | 1.23 | 10.48 | 5.91 | 1.84 | 0.91 | 2.55 | 8.03 | 1.79 |
| — | +627.3% | -95.2% | -10.9% | -72.6% | +35.6% | +311.4% | -26.5% | +2.7% | -38.5% | +3.7% | +30.1% | -60.7% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Genmab A/S's operating margin was 44.9% in Q3 2025, up 6.0 pp QoQ and up 7.0 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 35.9% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.4% | 94.3% | 93.8% | 94.1% | 94.8% | 95.1% | 96.4% | 95.5% | 97.3% | 98.3% | 99.5% | 100.0% | 100.0% |
| — | -0.8% | -2.7% | -1.5% | -2.6% | -3.3% | -3.1% | -4.5% | -2.7% | -1.7% | -0.5% | 0.0% | 0.0% | |
| Operating Margin | 31.1% | 44.9% | 38.9% | 26.3% | 33.5% | 37.9% | 30.3% | 19.2% | 35.7% | 35.8% | 35.2% | 14.7% | 50.1% |
| — | +18.4% | +28.5% | +36.7% | -6.1% | +6.1% | -14.0% | +30.7% | -28.8% | -24.3% | -10.7% | -39.3% | +62.3% | |
| Net Margin | 36.4% | 39.2% | 36.3% | 27.3% | 59.7% | 22.9% | 26.1% | 31.8% | 13.7% | 44.7% | 32.0% | 7.4% | 10.0% |
| — | +71.7% | +39.4% | -14.3% | +336.3% | -48.8% | -18.6% | +329.7% | +36.7% | -29.3% | -46.5% | -66.2% | -63.4% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 23.0% | 2.0% | 6.3% | 0.6% | 11.2% | 4.0% | 0.6% | 0.6% | 2.0% | 7.0% | 4.8% | 0.8% | 1.9% |
| — | -49.4% | +890.7% | -7.4% | +449.1% | -42.7% | -86.6% | -22.3% | +7.1% | -30.4% | -40.4% | -62.8% | -42.1% | |
| ROA | 19.3% | 1.7% | 5.2% | 0.4% | 9.0% | 3.2% | 0.5% | 0.5% | 1.8% | 6.3% | 4.3% | 0.7% | 1.7% |
| — | -48.3% | +864.0% | -15.8% | +395.7% | -48.3% | -87.4% | -23.1% | +7.3% | -29.5% | -40.7% | -63.0% | -42.6% | |
| ROIC | 22.2% | 2.3% | 6.5% | 0.5% | 6.0% | 5.8% | 0.8% | 0.5% | 7.1% | 7.0% | 6.4% | 1.9% | 11.1% |
| — | -61.1% | +753.7% | +8.7% | -16.5% | -16.5% | -88.1% | -74.2% | -35.6% | -22.6% | +0.4% | -33.3% | +143.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Genmab A/S's Debt/EBITDA ratio is 0.3x, down from 0.4x last quarter — comfortably within a safe range. The current ratio has improved 16.7% YoY to 6.03x, strengthening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 |
| — | -20.1% | -15.2% | -10.2% | +15.1% | +21.3% | +17.8% | +1.9% | +11.3% | +8.0% | +7.8% | +66.5% | +14.3% | |
| Debt / EBITDA | 0.14 | 0.30 | 0.39 | 4.60 | 0.46 | 0.45 | 4.08 | 7.83 | 0.45 | 0.45 | 0.53 | 1.76 | 0.23 |
| — | -34.0% | -90.3% | -41.3% | +2.8% | +0.7% | +672.6% | +344.8% | +96.0% | +42.0% | +8.9% | +143.7% | -53.5% | |
| Current Ratio | 5.25 | 6.03 | 6.22 | 6.22 | 5.25 | 5.17 | 5.03 | 12.46 | 13.34 | 11.38 | 14.93 | 14.44 | 15.48 |
| — | +16.7% | +23.7% | -50.1% | -60.7% | -54.6% | -66.3% | -13.7% | -13.8% | +18.3% | +13.8% | -16.6% | +6.8% | |
| Quick Ratio | 5.24 | 6.01 | 6.20 | 6.20 | 5.24 | 5.15 | 5.02 | 12.42 | 13.32 | 11.36 | 14.90 | 14.44 | 15.48 |
| — | +16.7% | +23.5% | -50.1% | -60.7% | -54.6% | -66.3% | -14.0% | -14.0% | +18.1% | +13.6% | -16.6% | +6.8% | |
| Interest Coverage | 55.86 | 153.00 | 40.00 | 37.60 | 40.00 | 116.78 | 12.42 | 29.00 | 278.33 | 210.63 | 209.71 | 69.50 | 515.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonGenmab A/S's current P/E is 15.4x. The average P/E over the last 4 quarters is 7.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Genmab A/S's current operating margin is 31.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Genmab A/S's business trajectory between earnings reports.